Plain-English translation of NCT06059495 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating early-stage stomach cancer. Instead of going straight to surgery, patients will receive , an immunotherapy drug that helps the body's immune system fight cancer cells. The study wants to see if some patients can achieve a complete response to this medication and potentially avoid surgery altogether.
Surgery to remove the stomach is the standard treatment for early-stage gastric cancer, but it can cause serious side effects and reduce quality of life. Researchers believe this medication works very well in patients whose tumors have certain genetic changes, so they want to test whether it could replace or delay surgery for these patients.
You likely qualify if…
You likely don't qualify if…
You will receive intravenously every three weeks for 4 cycles (about 12 weeks total). Throughout treatment and afterward, you will have regular endoscopy procedures (a camera down your throat) with biopsies to check how your tumor is responding. The study team will closely monitor you to see if your cancer disappears completely, and if it does, they will use a "watch-and-wait" approach—meaning careful monitoring instead of immediate surgery.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
France